SPIESS 6 , J. SCHIRREN 7 , W. EBERT 1 , W. FIEHN 8 , T. LUTHER 2 ,

Werle et al: Prognostic Factors in Non-small Cell Lung Cancer

69 Hackel CG, Krueger S, Grote HJ, Oshiro Y, Hodges S, Johnston Rudolf Z, Zargi M, Krasovec M, Svetic B, Kopitar-Jerala N and

59 Budihna M, Strojan P, Sˇmid L, Sˇkrk J, Vrhovec I, Zupevc A,

DA, Johnson ME, Roessner A, Ayala AG and Czerniak B: Kos J: Prognostic value of cathepsins B, H, L, D and their

Overexpression of cathepsin B and urokinase plasminogenactivator endogenous inhibitors stefins A and B in head and neck

is associated with increased risk of recurrence and metastasis in carcinoma. Biol Chem Hoppe-Seyler 377: 385-390, 1996.

patients with chondrosarcoma. Cancer 89: 995-1003, 2000.

70 Otto FJ, Goldmann T, Biess B, Lippold A, Suter L and Prognostic significance of cysteine proteinases cathepsins B and

60 Strojan P, Budhina M, Smid L, Vrhovec L, Kos J and Skrk J:

Westhoff U: Prognostic classification of malignant melanomas L and their endogenous inhibitors stefins A and B in patients

by combining clinical, histological, and immunohistochemical with squamous cell carcinoma of the head and neck. Clin

parameters. Oncology 56: 208-214, 1999. Cancer Res 6: 1052-1062, 2000.

71 Yoshii A, Kageshita T, Tsushima H and Ono T: Clinical

61 Kawasaki G, Kato Y and Mizuno A: Cathepsin expression in oral relevance of cathepsin B-like enzyme activity and cysteine squamous cell carcinoma: relationship with clinicopathologic

proteinase inhibitor in melanocytic tumours. Arch Dermatol factors. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 4:

Res 287: 209-213, 1995.

446-454, 2002.

72 Sloane BF, Moin K, Sameni M, Tait LR, Rozhin J and Ziegler

G: Membrane association of cathepsin B can be induced by Kos J: Prognostic value of cathepsins B, D and stefins A and B

62 Smid L, Strojan P, Budihna M, Skrk J, Vrhovec I, Zargi M and

transfection of human breast epithelial cells with c- Ha-ras in laryngeal carcinoma. Eur Arch Otorhinolaryngol 254: 150-

oncogene. J Cell Sci 107: 373-384, 1994. 153, 1997.

73 Werle B, Ebert W, Klein W and Spiess E: Charge

63 Russo A, Bazan V, Gebbia N, Pizzolanti G, Tumminello FM, polymorphism in human lung cell pro-cathepsin B. Anticancer Dardanoni G, Ingria F, Restivo S, Tomasino RM and Leto G: Flow

Res 16: 49-54, 1996.

74 Strohmaier AR, Porwol T, Acker H and Spiess E: Tomography advanced laryngeal cancer. Relationship with clinicopathologic

cytometric DNA analysis and lysosomal cathepsin B and L in locally

of cells by confocal laser scanning microscopy and computer- parameters and prognostic significance. Cancer 76: 1757-1764, 1995.

assisted three-dimensional image reconstruction: localization of

64 Schmitt M, Harbeck N, Thomssen C, Wilhem O, Magdolen V, cathepsin B in tumor cells penetrating collagen gels in vitro. J Reuning U, Ulm K, Hofler H, Jänicke F and Graeff H: Clinical

Histochem Cytochem 45: 975-983, 1997 impact of the plasminogen activation system in tumor invasion

75 Hughes SJ, Glover TW, Zhu XX, Kuick R, Thoraval D, Orringer and metastasis: prognostic relevance and target for therapy.

MB, Beer DG and Hanash S: A novel amplicon at 8p22-23 Thromb Haemost 78: 285-296, 1997.

results in overexpression of cathepsin B in esophageal

65 Levicar N, Kos J, Blejec A, Golouh R, Vrhovec I, Frkovic- adenocarcinoma. Proc Natl Acad Sci USA 95: 12410-12415, 1998. Grazio S and Lah TT: Comparison of potential biological

76 Szpaderska AM and Frankfater A: An intracellular form of markers cathepsin B, cathepsin L, stefin A and stefin B with

cathepsin B contributes to invasiveness in cancer. Cancer Res urokinase and plasminogen activator inhibitor-1 and

61 : 3493-3500, 2001.

77 Lah TT, Clifford JL, Helmer K, Day N, Moin K, Honn KV, Detec Prev 26: 42-49, 2002

clinicopathological data of breast carcinoma patients. Cancer

Crissman JD and Sloane BF: Inhibitory properties of low

66 Niedergethmann M, Hildenbrand R, Wolf G, Verbecke CS, molecular weight cysteine proteinase inhibitors from human Richter A and Post S: Angiogenesis and cathepsin expression

sarcoma. Biochim Biophys Acta 993: 63-73, 1989. are prognostic factors in pancreatic adenocarcinoma after

78 Harbeck N, Schmitt M, Kates RE, Kiechle M, Zemzoum I, curative resection. Int J Pancreatol 28: 31-39, 2000

Jänicke F and Thomssen C: Clinical utility of uPA/PAI-1

67 Russo A, Bazan V, Migliavacca M, Zanna I, Tubiolo C, determination in primary breast cancer tissue for individualized Tumminello FM, Dardanoni G, Cajozzo M, Bazan P, Modica

therapy concepts. Clin Breast Cancer 3: 196-200, 2002.

G, Latteri M, Tomasino RM, Colucci G, Gebbia N and Leto G: Prognostic significance of DNA ploidy, S-phase fraction and tissue levels of aspartic, cysteine, and serine proteases in operable gastric carcinoma. Clin Cancer Res 6: 178-184, 2000.

68 Herszenyi L, Plebani M, Carraro P, de Paoli M, Roveroni G, Cardin R, Foschia F, Tulassay Z, Naccarato R and Farinati F:

Received June 7, 2004 Proteases in gastrointestinal neoplastic diseases. Clin Chim

Revised July 29, 2004 Acta 291: 171-187, 2000.

Accepted September 17, 2004